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Abstract
Introduction: Administrative claims data have not commonly been used to study the clinical effectiveness of
medications for rheumatoid arthritis (RA) because of the lack of a validated algorithm for this outcome. We created
and tested a claims-based algorithm to serve as a proxy for the clinical effectiveness of RA medications.
Methods: We linked Veterans Health Administration (VHA) medical and pharmacy claims for RA patients
participating in the longitudinal Department of Veterans Affairs (VA) RA registry (VARA). Among individuals for
whom treatment with a new biologic agent or nonbiologic disease-modifying agent in rheumatic disease
(DMARD) was being initiated and with registry follow-up at 1 year, VARA and administrative data were used to
create a gold standard for the claims-based effectiveness algorithm. The gold standard outcome was low disease
activity (LDA) (Disease Activity Score using 28 joint counts (DAS28) ≤ 3.2) or improvement in DAS28 by > 1.2 units
at 12 ± 2 months, with high adherence to therapy. The claims-based effectiveness algorithm incorporated biologic
dose escalation or switching, addition of new disease-modifying agents, increase in oral glucocorticoid use and
dose as well as parenteral glucocorticoid injections.
Results: Among 1,397 patients, we identified 305 eligible biologic or DMARD treatment episodes in 269 unique
individuals. The patients were primarily men (94%) with a mean (± SD) age of 62 ± 10 years. At 1 year, 27% of
treatment episodes achieved the effectiveness gold standard. The performance characteristics of the effectiveness
algorithm were as follows: positive predictive value, 76% (95% confidence interval (95% CI) = 71% to 81%);
negative predictive value, 90% (95% CI = 88% to 92%); sensitivity, 72% (95% CI = 67% to 77%); and specificity, 91%
(95% CI = 89% to 93%).
Conclusions: Administrative claims data may be useful in evaluating the effectiveness of medications for RA.
Further validation of this effectiveness algorithm will be useful in assessing its generalizability and performance in
other populations.
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Introduction
Large administrative claims databases are commonly
used to evaluate medication safety [1,2]. These data
sources have a number of advantages, including large
size, widespread availability, comprehensiveness and
high generalizability to the population being studied.
These databases typically capture medical diagnoses,
procedures, drug utilization, hospitalizations, costs and
mortality. The diagnostic and procedural codes are sub-
mitted by healthcare providers in the course of clinical
care and can be used alone or combined into a more
complex algorithm to identify conditions of interest to
researchers [3,4]. Algorithms are available to identify a
number of safety-related conditions, including hospital-
associated infections, myocardial infarction, stroke, gas-
trointestinal perforation, gastrointestinal bleeding and
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algorithms have been shown to have high validity com-
pared to a gold standard of medical record review.
Several studies have also confirmed the validity of var-
ious coding algorithms to identify arthritis-specific diag-
noses and procedures in different medical settings
[15-20]. However, the use of administrative data to
study the clinical effectiveness of medications for inflam-
matory arthritis, such as rheumatoid arthritis (RA), has
been limited by the lack of a validated algorithm to
serve as a proxy for clinical improvement in RA disease
activity. Our objective was to derive and test a claims-
based algorithm to serve as a proxy for the effectiveness
of medications for RA patients.
Materials and methods
Eligible patient population
After obtaining Institutional Review Board approval, we
used data from a cohort of patients diagnosed with RA
by a rheumatologist on the basis of the American Col-
lege of Rheumatology 1987 criteria [21]. These patients
were participants in the longitudinal Department of
Veterans Affairs (VA) RA registry (VARA), which has
been described elsewhere [22]. All VARA participants
provided their written informed consent. VARA con-
tains demographic, clinical and RA-specific information,
including the Disease Activity Score using 28 joint
counts (DAS28), as assessed by physicians using the
DAS28 [23] and the Clinical Disease Activity Index
(CDAI) [24], as well as a biorepository with banked
DNA, serum and plasma. VARA data have been col-
lected by rheumatologists at 11 VHA facilities through-
out the United States since 2003. We linked VARA
participants to the Veterans Health Administration’s
Medical SAS Datasets present in the VHA administra-
tive databases from 2002 to 2010 to obtain medical and
pharmacy claims.
Among VARA enrollees, we used claims data to iden-
tify eligible individuals in whom a biologic agent had
been initiated. Biologics of interest included abatacept,
adalimumab, etanercept, infliximab and rituximab. We
defined “initiation” as no prior use of that biologic agent
d u r i n gt h ep a s t6m o n t h s .E l i g i b l ep a r t i c i p a n t sm u s t
have had a baseline VARA visit on the same day or
within 1 month of biologic initiation. The date of initia-
tion of the biologic (the index date) defined the start of
a1 - y e a r“treatment episode.” T oc o n f i r mt h a tp a t i e n t s
were receiving medications through the VA system, eli-
gible individuals must have filled at least one prescrip-
tion (of any duration) for any oral medication during
the 6 to 12 months prior to the index date. Participants
must also have had a follow-up VARA visit that
occurred at 1 year ± 2 months after the index date. If
there was no VARA visit at 1 year, then these treatment
episodes were excluded, as there was no clinical gold
standard with which to compare the algorithm’sp e r f o r -
mance. VARA data were used only to capture the
DAS28, the CDAI and other clinical characteristics mea-
sured at the baseline and outcome VARA visits. All
o t h e rd a t au s e df o rt h ea n a l y s i sw e r ea b s t r a c t e df r o m
the administrative claims data.
To test the performance of the effectiveness algorithm
and to see whether it was similar for nonbiologic RA
treatments, we performed a separate analysis of RA
patients enrolled in VARA who were starting lefluno-
mide (LEF), sulfasalazine (SSZ) or hydroxychloroquine
(HCQ) and who also had any prior or current use of
methotrexate (MTX). New MTX users were not repre-
sented in this analysis, because MTX is typically consid-
ered an “anchor” drug for RA patients and generally is
continued even if the patient’s therapeutic response is
suboptimal, in contrast to other RA therapies, where the
drugs are typically discontinued if they are not effective.
Because of similarities in both the descriptive character-
istics of the study populations of biologic and nonbiolo-
gic disease-modifying anti-rheumatic drug(DMARD)
users and the performance characteristics of the effec-
tiveness algorithm between biologic and DMARD treat-
ment episodes, the data are shown throughout for the
biologic users as a unique group and for a combined
group of new biologic and nonbiologic DMARD users.
The clinical effectiveness outcome and the effectiveness
algorithm
The gold standard for effectiveness was measured at the
1 year VARA visit following the index visit and was
defined as DAS28 ≤ 3.2 units (low disease activity
(LDA)) or improvement in DAS28 > 1.2 units [25,26].
The gold standard also required that the patient have
high adherence to biologic treatment (for example, med-
ication possession ratio for oral or injectable biologic
therapy ≥ 80%) (see Table 1 for further details). The
purpose of the adherence requirement was to maximize
confidence that observed changes in disease activity
were more likely attributable to the treatment started on
the index date rather than to natural variations in dis-
ease activity, switching to a different RA medication
after the index date, or other factors.
The claims-based effectiveness algorithm described in
Table 1 incorporates factors (selected ap r i o r ibased
upon content knowledge) that were expected to be asso-
ciated with suboptimal clinical response and would be
available within typical administrative claims data
sources without laboratory results. The components of
the effectiveness algorithm included increase in biologic
dose compared to the starting dose; switch to a different
biologic; addition of a new nonbiologic DMARD, includ-
i n gM T X ,S S Z ,L E Fa n dH C Q ;i n i t i a t i o no fc h r o n i c
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prescriptions during the 6 months prior to the index
date); increase in glucocorticoid dose during months 6
to 12 (for those who received any oral glucocorticoid
prescriptions in the 6 months prior to the index date);
and more than one parenteral or intraarticular injection
on unique days after the patient had been receiving the
new treatment for more than 3 months. Each of these
factors was included in the algorithm as a series of
dichotomous conditions that were either satisfied or
not. Patients must have satisfied all conditions to have
met the effectiveness rule.
Statistical analysis and additional sensitivity analyses
We calculated the performance characteristics, including
positive predictive value (PPV), negative predictive value
(NPV), sensitivity (Se) and specificity (Sp), to compare
the effectiveness algorithm to the effectiveness gold
standard, and we used the binomial distribution to cal-
culate 95% confidence intervals. Because patients were
allowed to contribute multiple treatment episodes, we
performed an additional analysis where all patients were
permitted to contribute only one treatment episode
each. This approach was felt to be more conservative
than alternate strategies, such as using generalized
estimating equations that account for the within-person
variance by widening the confidence intervals of the
PPV, NPV, Se and Sp, but leave the point estimates
unchanged.
For all treatment episodes where there was discor-
dance between the administrative data-based effective-
ness rule and the gold standard for clinical effectiveness,
we abstracted additional data from the medical records
using a structured case report form developed to
descriptively inform the reason for discordance.
Although not explicitly part of the effectiveness rule,
we also identified comorbidities (posttraumatic stress
disorder, low-back pain, fibromyalgia, hepatitis C and
depression) that were hypothesized to be associated with
worse patient global scores independently of RA disease
activity. As part of a sensitivity analysis, we restricted
the cohort to patients without any of these ICD-9 codes.
As part of two additional sensitivity analyses, we
dropped the requirement that patients have a baseline
VARA visit. This allowed for inclusion of a modest
number of additional VARA treatment episodes where
only an outcome VARA visit (but not a baseline VARA
visit) was available. In these sensitivity analyses, clinical
effectiveness was defined by low disease activity as (1)
DAS28 ≤ 3.2 with high adherence or (2) CDAI < 11
Table 1 Components of the effectiveness algorithm, assessed between the index date and the outcome visit date
approximately one year later
Criteria* Description and implementation
High adherence to index drug
(required)
For etanercept, adalimumab and oral medications, must be ≥ 80% adherent to therapy, calculated as a
medication possession ratio [38]
For infliximab, must have received at least the number of infusions expected between the index and
outcome visit dates to conform to a schedule of 0, 2, 6 and 14 weeks and every 8 weeks thereafter
For abatacept, must have received the number of infusions expected between the index and outcome
visit dates to conform to a schedule of once-monthly dosing; missing one infusion is permissible
For rituximab, criterion is not applicable
Biologic switch or add (prohibited) Between the index and outcome visit dates, patient cannot initiate therapy with a new biologic agent
Addition of a new nonbiologic DMARD
(prohibited)
Between the index and outcome visit dates, patient cannot initiate therapy with a new nonbiologic
DMARD (methotrexate, sulfasalazine, leflunomide or hydroxychloroquine) that they were not already
taking during the 6 months prior to the index date
Increase in biologic dose or frequency
(prohibited)
For etanercept and adalimumab, dose escalation of etanercept to 50 mg twice weekly or adalimumab 40
mg once weekly is prohibited
For infliximab, difference between ending and starting dose, with each dose rounded up to the nearest
100 mg cannot be ≥ 100 mg. The number of infusions must be within 120% of the number expected
assuming a 0-, 2-, or 6-week load and an 8-week infusion schedule
For abatacept, difference between ending and starting dose cannot be ≥ 100 mg
For rituximab, criterion is not applicable
More than one glucocorticoid joint
injection (prohibited)
Cannot receive glucocorticoid injections† on more than one unique calendar day between the index date
+ 90 days and the outcome visit date, inclusive
Increase in dose of oral glucocorticoid
(prohibited)
For patients who received no prescriptions for oral glucocorticoids during the 6 months prior to the index
date, cannot have received more than 30 days of oral glucocorticoids between the index date + 90 days
and the outcome visit date, inclusive
For patients who received prescriptions for oral glucocorticoids in the 6 months prior to the index date,
the cumulative glucocorticoid dose in the 6 months prior to the outcome visit date must be similar (that
is, within 120%) to the cumulative dose in the 6 months prior to the index visit date
DMARD: disease-modifying agent in rheumatic disease. †Glucocorticoid injection CPT codes: 20600, 20605, 20610. *All criteria must be satisfied to have met the
effectiveness algorithm.
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SAS 9.2 software (SAS Institute, Cary, NC, USA).
Results
The characteristics of the VARA participants were mea-
sured at the start of each treatment episode. Because
the characteristics of VARA patients at the start of non-
biologic DMARD treatment episodes were similar to
those of the biologic treatment episodes, these data were
pooled and are shown in Table 2 as biologic treatment
episodes (left column) and a combined group of biologic
or nonbiologic DMARD treatment episodes (right col-
umn). As shown, and consistent with expectations for
this RA population of US veterans [27], 94% were male,
the majority were Caucasian and there was a high preva-
lence of current or past smoking. The most commonly
initiated biologic was adalimumab (38%). For all eligible
biologic treatment episodes (n = 197), patients had high
s t a r t i n gd i s e a s ea c t i v i t ya se v i d e n c e db yam e a nD A S 2 8
of 5.0, a mean tender joint count of 9.6 and a mean
swollen joint count of 7.9. After combining the biologic
treatment episodes with the DMARD treatment episodes
(n = 305 total), the descriptive characteristics of the eli-
gible cohort remained similar (right column in Table 2).
The primary results of the study are shown in Tables
3 and 4. Among patients treated with biologics (Table
3), a total of 28% of treatment episodes were deemed
effective based upon the patients’ remaining on therapy
and achieving either low disease activity (mean DAS28 ≤
3.2) and/or a 1.2 unit improvement in DAS28. The PPV
and NPV of the administrative data-based effectiveness
algorithm were 75% and 90%, respectively. The sensitiv-
ity of the effectiveness algorithm was 75%, and its speci-
ficity was 90%. If patients were restricted to contributing
only one treatment episode (n = 161 unique patients),
the PPV was 76% and the NPV was 91%.
Among the biologic users in Table 3, the most com-
mon reasons why patients failed to meet the effective-
ness algorithm criteria were suboptimal adherence,
discontinuation and/or switching to a different biologic
agent (n = 118, 60%); glucocorticoid dose increase (n =
30, 15%); addition of new nonbiologic DMARDs (n =
Table 2 Baseline characteristics of VARA participants at the start of each biologic treatment episode
Characteristics Biologics only (N = 197) Biologics or DMARDs* (N = 305)
Patient demographics
Age, years 60.9 ± 10.3 62.3 ± 10.4
Males 185 (94%) 287 (94%)
Race/ethnicity
Caucasian, non-Hispanic 159 (81%) 248 (81%)
Non-Caucasian, Hispanic 7 (4%) 8 (3%)
Black, non-Hispanic 27 (14%) 45 (15%)
American Indian or Pacific Islander 4 (2%) 4 (1%)
RA drug initiated
Abatacept 9 (5%) 9 (3%)
Adalimumab 74 (38%) 74 (24%)
Etanercept 60 (31%) 60 (20%)
Infliximab 34 (17%) 34 (11%)
Rituximab 20 (10%) 20 (7%)
Hydroxychloroquine n/a 63 (21%)
Leflunomide n/a 20 (7%)
Sulfasalazine n/a 25 (8%)
RA-related characteristics
DAS28 5.0 ± 1.5 4.9 ± 1.6
CDAI (0-76) 30.2 ± 16.3 27.5 ± 15.2
Physician global (0 to 100) 51.0 ± 22.1 50.3 ± 22.6
Patient global (0 to 100) 57.4 ± 25.2 54.8 ± 24.2
Tender joint count (0 to 28) 9.6 ± 8.6 8.5 ± 7.9
Swollen joint count (0 to 28) 7.9 ± 7.2 7.8 ± 6.6
MDHAQ (0 to 3) 1.2 ± 0.6 1.2 ± 0.6
ESR, mm/hour 27.9 ± 23.3 29.9 ± 24.6
CRP, mg/dL 1.9 ± 2.4 2.1 ± 2.5
Data are n (%) or means ± SD. DMARD: disease-modifying agent; RA: rheumatoid arthritis; CDAI: Clinical Disease Activity Index; CRP: C-reactive protein; DAS28:
Disease Activity Score in 28 joints; MDHAQ: Multi-Dimensional Health Assessment Questionnaire; ESR: sedimentation rate; n/a: not applicable; SD: standard
deviation. *Includes hydroxychloroquine, leflunomide and sulfasalazine.
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cocorticoid initiation (n =1 0 ,6 % ) ;a n dm o r et h a no n e
joint injection (n = 11, 6%). The results of the sensitivity
analysis that excluded biologic treatment episodes for
patients with any of the several comorbidities of interest
(33%, n = 131 treatment episodes remaining) yielded a
slightly higher PPV (81%) and a similar NPV (89%)
compared to the main analysis.
The performance characteristics of the combined
cohort that included both biologic and nonbiologic
treatment episodes are shown in Table 4 and were gen-
erally quite similar to the PPV and NPV shown for the
biologic treatment episodes in Table 3. Further details
obtained from medical record review were available for
the patients in the off-diagonal (discordant) cells given
in Table 4 and are shown in Table 5. For the 19 treat-
ment episodes where the effectiveness algorithm criteria
were satisfied but the gold standard criteria were not,
the most common reasons found were either that an
inadequate clinical response was recognized but medica-
tion changes were precluded because of new or wor-
sened comorbidities, or the physician and/or the patient
was satisfied with the level of disease activity, even
though the patient did not meet the DAS28 criteria for
low disease activity or improvement. For the 23 treat-
ment episodes in which the effectiveness algorithm cri-
teria were not satisfied but the gold standard criteria
were, the most common reasons were an increase in the
dose of oral glucocorticoids and the addition of new
nonbiologic DMARDs.
The extent of bias resulting from misclassification of
our algorithm is described in Table 6. After varying a
hypothetical response rate as measured by the algorithm
from 30% and 60%, the amount of bias compared to the
true response rate ranged from 1% to 21%.
The results of the second sensitivity analysis that had
no baseline VARA visit (and thus could not include
change in disease activity as part of the effectiveness
gold standard) but included all patients, regardless of
comorbidities, are shown in Additional file 1. Many
more treatment episodes were available (n =3 8 0f o r
biologic treatment episodes and n = 699 for biologic or
DMARD treatment episodes). Approximately 20% of
patients achieved the effectiveness gold standard, which
in this analysis was low disease activity (DAS28 ≤ 3.2).
The NPV of the effectiveness algorithm was high (92%),
but the PPV was substantially lower (49%). After substi-
tuting CDAI < 11 for DAS28 ≤ 3.2 as the gold standard
for clinical effectiveness in the third sensitivity analysis,
the results were nearly identical (data not shown).
Discussion
We developed a novel, administrative data-based clinical
effectiveness algorithm for use in future studies as a
proxy for the clinical effectiveness of RA medications. In
this preliminary assessment of its performance, we
showed that it has acceptable sensitivity, specificity, PPV
and NPV. Our sensitivity, specificity, PPV and NPV that
were in the 75% to 90% range reflect good, although not
perfect, performance of our effectiveness algorithm
Table 3 Comparison of effectiveness algorithm versus effectiveness gold standard for biologic users
Effectiveness gold standard*
Met effectiveness algorithm** Yes No Total PPV (95% CI) NPV (95% CI)
Yes 42 14 56 (28%) 75% (62 to 86)
No 14 127 141 (72%) 90% (84 to 94)
Total 56 (28%) 141 (72%) 197 (100%)
Se 75%
(95% CI = 62 to 86)
Sp 90%
(95% CI = 84 to 94)
CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value; Se: sensitivity; Sp: specificity. *DAS28 ≤ 3.2 or DAS28 improvement by > 1.2
units and high adherence (for example, ≥ 80%) to the biologic started on the index date. **The components of the effectiveness algorithm are shown in Table 1.
Table 4 Comparison of effectiveness algorithm versus effectiveness gold standard for biologic and nonbiologic
disease-modifying agent in rheumatic disease** treatments
Effectiveness gold standard***
Met effectiveness algorithm* Yes No Total PPV (95% CI) NPV (95% CI)
Yes 60 19 79 (26%) 76% (71 to 81)
No 23 203 226 (74%) 90% (88 to 92)
Total 83 (27%) 222 (73%) 305 (100%)
Se = 72%
(95% CI = 67 to 77)
Sp = 91%
(95% CI = 89 to 93)
CI: confidence Interval; DMARD: disease-modifying; NPV: negative predictive value; PPV: positive predictive value; Se: sensitivity; Sp: specificity. *The components
of the effectiveness algorithm are given in Table 1. **DMARDs include hydroxychloroquine, leflunomide and sulfasalazine. ***Defined as DAS28 ≤ 3.2 or DAS28
improvement by > 1.2 units and high adherence (for example, ≥ 80%) to the biologic and/or DMARD started on the index date.
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ison, the corresponding performance characteristics of
administrative data for a number of rheumatology con-
ditions, including diagnoses for RA, spondyloarthropa-
thies, systemic lupus erythematosus, fibromyalgia,
osteoarthritis, joint injection and joint replacement pro-
cedures [15-20] were similar and ranged from approxi-
mately 80% to 95%. Besides a new or worsened
comorbidity, the most common reason why patients
met the effectiveness algorithm criteria but failed to
meet the gold standard criteria was that the physician
and patient were satisfied with the level of disease activ-
ity, despite not having achieved low disease activity or
an improvement in the DAS28 by ≥ 1.2 units. In this
circumstance, providers may feel that the patient is get-
ting at least some benefit from the drug and that the
clinical response is adequate to continue its use. It is
also possible that quantitative disease activity measures
such as the DAS28 may not adequately capture underly-
ing RA disease activity for some patients (for example,
those with concomitant fibromyalgia). Moreover,
patients may fear that their condition will worsen after
s w i t c h i n gt oan e wt h e r a p yo rm a yh a v et r e p i d a t i o n
regarding new side effects [28], and therefore they may
be reluctant to change medications. Further studies are
needed to validate the effectiveness algorithm in other
data sets and RA patient populations. However, these
results are encouraging and suggest that administrative
data can be used to estimate medication effectiveness
for RA patients.
As our gold standard for medication effectiveness, we
selected low disease activity (DAS28 ≤ 3.2) or improve-
ment in DAS28 by > 1.2 units. It might be argued that
these criteria are not stringent enough, although they
are broadly consistent with (albeit not identical to) the
European League Against Rheumatoid Arthritis
(EULAR) responder definition [26]. Consistent with our
focus on the DAS28, results from a preference analysis
found that RA disease activity score (also measured
using the DAS28) was the most important factor in
rheumatologists’ decisions to escalate care [29]. The
Table 5 Reasons for discordance between the effectiveness algorithm and the effectiveness gold standard
Reasons for discordance Satisfied effectiveness algorithm, did
not meet effectiveness gold standard
(false-positives)
(n = 19)
Did not satisfy effectiveness
algorithm, met effectiveness gold
standard (false-negatives)
(n = 23)
Presumed reasons for not meeting gold standard, obtained
from medical record review
Biologic change deferred in light of concerns for new/
worsened comorbidity
10 -
Clinically stable or improved and patient/physician
satisfied, but DAS and DAS change did not meet gold
standard effectiveness criteria
4-
Physician recognized inadequate response, but chose to
retreat with rituximab only after 1 year
2
Receiving some medications (for example,
glucocorticoids) outside of the VHA system
1-
Biologic change deferred in light of surgery or
procedure
1-
Physician recommended biologic change or dose
change, but patient declined
1-
Noncompliance with nonbiologic RA medications 1 -
Components of the effectiveness algorithm that were not
met despite having met the effectiveness gold standard
Glucocorticoid dose increase or initiation - 15
Added new DMARD(s) - 6
Increase in biologic dose and/or frequency - 2
VHA: Veterans Health Administration; RA: rheumatoid arthritis; DMARD: disease-modifying. Data shown are the number of treatment episodes in the off-diagonal
cells given in Table 4. Column totals may sum to > 100% because there may be multiple reasons why patients did not meet the effectiveness gold standard or
the effectiveness algorithm. -, criterion is not applicable.
Table 6 Extent of bias associated with misclassification*
of the effectiveness algorithm according to observed
response rate
Observed response
rate
True response
rate**
Bias (observed-true)/true
(%)
30% 30% < 1%
40% 36% 10%
50% 43% 16%
60% 49% 21%
*From Table 4, where the positive predictive value (PPV) was 76% and the
negative predictive value (NPV) was 90%. **Computed as True rate =
Observed rate × (PPV + NPV-1)-NPV + 1 [39]. Numbers are rounded to the
nearest whole integer but the actual values were used to calculate the bias.
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ers of North America (CORRONA) registry showed that
low disease activity or a DAS28 improvement > 1.2
units was sufficient for the majority of patients to con-
tinue treatment with biologic therapy [30]. As part of a
sensitivity analysis, we modified our gold standard to
require patients to achieve only LDA (DAS28 ≤ 3.2) and
did not include patients who achieved only some
improvement (change in DAS28 ≥ 1.2) in the absence of
LDA. This lowered the PPV, indicating that many
patients had clinical improvement but did not achieve
LDA. Many of these patients were continued on ther-
apy, suggesting that both the patients and physicians
were in many cases satisfied enough with the response.
We also note that the DAS28 response rate (approxi-
mately 30%) (Table 3) observed for our clinical effective-
ness gold standard was relatively low. However, given
the comorbidity profile and other characteristics of the
RA patients enrolled in VARA [31], response rates are
typically lower than those reported in clinical trials of
more selectively included RA patients with fewer comor-
bidities [32].
Another component of our gold standard is that we
required that patients have high (that is, ≥ 80%) adher-
ence to their medication regimen. We recognize that
any threshold for adherence is arbitrary. Requiring ≥
80% compliance is conventional and has been used
when studying other conditions, such as osteoporosis
and cardiovascular disease [33-36]. The main purpose of
the adherence requirement was to focus on medication
effectiveness. Medications that the patient does not con-
tinue, whether for reasons of inefficacy, safety, tolerabil-
ity or something else, are not effective. Adherence has
been required in other observational analyses of com-
parative effectiveness in RA [37]. Also, we wanted to
maximize confidence in the patient’s disease activity’s
being attributable to the RA treatment started on the
index date rather than on a medication that was later
substituted because the previous medication begun on
the index date had failed. Finally, the requirement of
continued adherence to the RA therapy is consistent
with clinical trial methodology in which patients who do
not adhere to the study protocol, including continuing
to take the medication, are generally excluded from the
trial. These patients’ outcomes are often imputed as
nonresponse, which is the same classification to which
they were assigned in our effectiveness algorithm.
Although many of the elements of our effectiveness
algorithm are intuitive, a few deserve special mention.
The requirement that patients not initiate or escalate
the dose of oral glucocorticoids assumes that the domi-
nant prescribing indication for glucocorticoids is RA.
For patients who may have another indication for gluco-
corticoids (for example, chronic obstructive pulmonary
disease, which is very common in VHA patients), this
criterion may not perform optimally. As described in
Table 5, this issue was the most common reason why
patients failed the effectiveness algorithm. Our algorithm
might be expected to perform better in other RA popu-
lations that have been shown to have a lower prevalence
of comorbidities for which systemic glucocorticoids are
used [31]. We also limited then u m b e ro fi n t r a a r t i c u l a r
injections allowable to no more than 1 unique day on
which the patient received such injections. VA physi-
cians are not directly compensated for these injections
and other procedures and therefore are likely to under-
report them. For this reason, our effectiveness algorithm
may perform better when there is a financial incentive
to code these procedures more accurately. We also
found certain comorbidities (for example, fibromyalgia
and depression) were common, and we hypothesized
that they might be associated with high patient global
scores even if the patient’sR Ai su n d e rg o o dc o n t r o l .
This is not a unique feature of the VARA cohort or our
study, but is potentially problematic for the measure-
ment of patient-reported outcomes in all RA studies
that include patients with these conditions. Restricting
the population to individuals without these comorbid-
ities improved the PPV of our effectiveness algorithm by
6%, but limits our study’s generalizability as it excluded
one-third of our data.
The strengths of our study include evaluation of a
large number of patients participating in a RA registry
at 11 VA medical centers. All patients had rheumatolo-
gist-confirmed RA and well-characterized measures of
RA disease activity. The novel linkage between the regis-
try and the national VHA administrative data made
developing and testing of our effectiveness algorithm
possible. Additionally, there are strong financial incen-
tives for RA patients to fill their biologic medications
within the VHA system, and it is likely that most if not
all RA medications were captured in the VHA adminis-
trative data. Despite these strengths, we acknowledge
the potentially limited generalizability of patterns of care
in the VHA system, and the possible dissimilarity in the
RA patients who receive treatment in that system, com-
pared to other RA populations. However, sensitivity
andspecificity, unlike PPV and NPV, should be less
dependent on the prevalence in the population, and
more reflective of the test itself, thereby decreasing the
impact of any unique features of the VA population.
Moreover, we might expect that the PPV and NPV of
the algorithm might perform better in other RA cohorts,
given the higher prevalence of comorbidities in this
VARA population compared to other RA cohorts [31].
We also acknowledge that while the effectiveness algo-
rithm, which was based upon factors selected from con-
tent knowledge, appeared to perform well and have
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Page 7 of 9good face validity in VARA, further validation in more
recently recruited VARA participants who were not
included in our sample, and in different RA cohorts
where there is a link to administrative data, is needed to
confirm our algorithm’s robustness. We also recognize
that using more empirical approaches to let the data
guide optimization of the algorithm would be desirable,
but substantially more data would be required for this
approach and for validation. Finally, as an additional
opportunity to extend the algorithm in the future, we
note that our effectiveness outcome was measured at 1
year, and assessing effectiveness at other time points
(for example, at 6 and 24 months) is important.
Although we expect similar performance of the algo-
rithm at these different time points, this hypothesis
remains to be confirmed.
Conclusions
In conclusion, the results of this work provide a preli-
minary mechanism with which to evaluate the effective-
ness of RA medications on the basis of administrative
claims and pharmacy data. While clinical disease activity
measures remain the gold standard for assessing effec-
tiveness in RA, the many large administrative data
sources in the United States and internationally are an
as yet untapped resource that might be used to assess
effectiveness in large real-world populations of RA
patients.
Additional material
Additional file 1: Sensitivity analysis comparing the effectiveness
algorithm to an alternate definition of the effectiveness gold
standard. Table S1 Sensitivity analysis comparing the effectiveness
algorithm to an alternate definition of the effectiveness gold standard for
biologic users. Table S2 Sensitivity analysis comparing the effectiveness
algorithm to an alternate definition of the effectiveness gold standard for
biologic and nonbiologic disease-modifying agent in rheumatic disease
treatments.
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